Juluca combines GSK’s already approved integrase inhibitor Tivicay (dolutegravir) with Janssen’s non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine), to produce a regimen that ...

It already has a two-drug regimen, Juluca, which was approved in Europe in May, and by the FDA last year. The studies compared the two drug regimen with dolutegravir and a standard “backbone ...

During the fourth quarter, GSK and J&J’s Juluca and Dovato contributed around 39% to total HIV sales. While sales of the dolutegravir franchise were down 1% at CER in the U.S. market ...